Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Proteostasis Therapeutics (NYSE:PTI)

Organization & Developments: Proteostasis Therapeutics

Parents

2013: Proteostasis, Biogen Team up on Protein Homeostasis Drugs
2018: Proteostasis Therapeutics Surges On Cystic Fibrosis Data, Can The Run Continue?_seekingalpha.com
2018: Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance_shares exploded upward by 301%
2018: Proteostasis Therapeutics' FDA Breakthrough Therapy Designation Gives It An Edge - Proteostasis Therapeutics (NYSE:PTI)
2018: Why This ~$6 'Busted IPO' Has Been On The Rise - Bret Jensen
2019: Phase 2 data from its cystic fibrosis trial due by the end of the year.
2019: Proteostasis Recruits Patients Quicker Than Anticipated, Results From CF Studies Now Expected Q4 2019_seekingalpha.com
2019: The Upcoming Readout For Proteostasis Is In A Make Or Break Situation_seekingalpha.com
Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as Alzheimer’s disease, emphysema, Huntington’s disease, and type II diabetes.
Seeking to develop neurological drugs in partnership with Elan
The Proteostasis Network interacts with proteins to ensure that each protein within a cell makes it to where it needs to go, properly folded with the correct functionality, or is degraded and purged to prevent damage.